A recent study seems to be getting some traction in the...

A recent study seems to be getting some traction in the Cosmetics/Cosmecuticals arena :

https://www.cosmeticsandtoiletries.com/home/news/22005988/inflammatory-skin-conditions-drive-patient-interest-in-cannabis

The paper is "Consumer Perspectives on and Utilization of Medical Cannabis to Treat Dermatologic Conditions" and came out of the George Washington University School of Medicine and Health Sciences, Washington, DCb and The University of Maryland, College Park, MD. It is a market questionnaire of end-users.

A link to the abstract is :

https://jddonline.com/articles/consumer-perspectives-on-and-utilization-of-medical-cannabis-to-treat-dermatologic-conditions-S1545961622P0031X/

The paper makes the statement that "a 2019 study found that 80% of Canadian medical marijuana dispensaries listed indications for dermatologic MCPs that were not medically proven."

I wonder if any of this steps on either BOT's patents or, more broadly, that use of an "un-tested" - and therefore suspect - faux-therapeutic good (and the associated "wellness" claims) could consequently harm BOT's pharmaceutical efficacy claims?